Top 100 Pharma Companies by Payments to Physicians

The CMS Open Payments dataset records payments from pharmaceutical and medical device companies to physicians, teaching hospitals, and other providers. This ranking surfaces the top 100 companies by aggregate payments to U.S. physicians, derived from general payment records ingested into PlainPharmaWatch. Top 10 companies account for 48.1% of top-100 payment volume, indicating concentration among major players.Source: CMS Open Payments, https://openpaymentsdata.cms.gov/summary

Top 10 companies by total payments

Top 100 ranking (full list)

Methodology

Aggregations are based on CMS Open Payments general payments published by the Centers for Medicare and Medicaid Services. Recipients are filtered to physician taxonomy (NPI type 1) and amounts summed by applicable manufacturer or applicable GPO making the payment. Physician counts reflect unique NPI identifiers. Payment type counts reflect distinct associated_payment_types per company. The page is SSR-rendered directly from the latest ingested DB snapshot, top-100 cutoff is computed live by descending total payments.Source: PlainPharmaWatch ETL, portal-plainpharmawatch

Caveats and Limitations

Payments represent company-submitted data, subject to amendments and potential inaccuracies; CMS publishes amended data quarterly. Values include all four CMS Open Payments categories: general payments (consulting, meals, travel), research payments tied to clinical trials, ownership/investment interests, and interest payments; company profile pages break out general payments by sub-category but do not separately itemize research, ownership, or interest payments. High volumes do not indicate misconduct, as many support legitimate education, consulting, research, and royalty arrangements. Subsidiary payments are aggregated when the upstream identifier links them, though different national or corporate subsidiaries of the same parent (for example, distinct US, international, and regional entities) may be listed separately when CMS records them under separate identifiers. For full per-company detail, explore company profiles.

Context for the top-100 list

The pharmaceutical industry's payment footprint in the United States is dominated by a comparatively small set of manufacturers. The top ten companies in this list, led by Novartis Pharmaceuticals Corporation at $676.0M and Pfizer Inc. at $673.7M - together account for 48.1% of all top-100 disbursements. That concentration reflects the structural reality of the industry: specialty therapeutics for oncology, immunology, neurology, and cardiology require high-touch clinical engagement, and the manufacturers selling those drugs deploy large field-medical and key-opinion-leader programs. The smaller manufacturers on the list (ranks 50 through 100) typically focus on narrower indications, generics with specialty distribution requirements, or device subsidiaries.

Each rank is computed against the live PlainPharmaWatch companies table on every request. Click any company name in the table above to drill into the per-company detail page, which breaks the company's reported total down by payment category (consulting, food and beverage, royalties, travel, speaking, education, ownership, and others), shows the top individual recipient physicians and teaching hospitals, and offers links to the same data as the company filed it with CMS. The detail page also surfaces transaction-count, distinct-payment-type-count, and average-amount-per-transaction metrics, three orthogonal lenses on the same disbursement footprint.

How to use these rankings

For journalists and academic researchers, the top-100 list is most useful as a starting point for investigating prescribing-payment relationships in a specific therapeutic area. Identify the manufacturers with significant exposure in the area you care about (oncology, antidiabetic agents, anticoagulants, hepatitis-C therapies, etc.), then cross-reference the top recipient pages to find the physicians most heavily engaged. For physicians evaluating their own footprint, the per-company detail page links each manufacturer back to the underlying NPI-level recipient table, your name will appear there if any reported payment of any size was made.

For policy researchers, the geographic skew is the most informative angle: aggregate by state and you see that a small number of states, typically those with concentrations of academic medical centers and large physician populations, capture a disproportionate share of payment volume. Cross-reference with the top-50 state ranking for the geographic complement to this company-level view, or the main rankings hub for the per-physician and most-transactions cuts. The methodology page documents every step of the ingestion pipeline. Looking for narrative context instead of the full sortable table? The top-10 research analysis covers the same leaders in prose depth, and the consumer guide to top pharma spenders explains what the figures mean without the table.

What payment-category mix reveals about a manufacturer

Aggregate payment volume tells you how active a manufacturer is. The mix of payment categories tells you what that manufacturer is buying. Manufacturers whose payment mix is dominated by consulting fees and speaker-bureau compensation are typically running high-touch sales models targeted at high-prescriber specialists in a narrow therapeutic area. Manufacturers whose mix is dominated by food and beverage and travel are typically running broad sales-rep coverage models in larger therapeutic areas. Manufacturers whose mix includes a meaningful royalty component are typically generating payments from licensed inventions or co-developed intellectual property, often tied to specific surgical devices or platform technologies. Manufacturers with a large research-payment component are concentrating their disclosed transfers in clinical-trial work routed through teaching hospitals.

The per-company detail pages on PlainPharmaWatch decompose each manufacturer's total into these category buckets, so a researcher comparing two manufacturers at similar absolute payment volumes can immediately see whether they are operating fundamentally different commercial models. The same decomposition is available at the state level, California's mix differs meaningfully from New Jersey's mix, and that compositional difference reflects the different industry footprints of those states. Click any company name in the table above to drill into the per-category breakdown.

Cross-checking against alternative pharma-spending datasets

The CMS Open Payments dataset captures direct transfers of value from manufacturers and group purchasing organizations to U.S. physicians and teaching hospitals. It is not the only pharmaceutical-spending measure available, and it is worth understanding what it does and does not include. Direct-to-consumer advertising spending is tracked by entirely separate commercial measurement firms and is not in Open Payments. Wholesale-acquisition-cost spending, the prices paid by hospitals and pharmacies for the drugs themselves, is tracked by Medicare Part B and Part D claims data and by Medicaid drug-utilization reports, neither of which appears here. Research-and-development expense at the corporate level is disclosed in 10-K filings with the Securities and Exchange Commission. Each of these data sources answers a different question; Open Payments answers specifically the question of how much each manufacturer transferred directly to identified U.S. physicians and teaching hospitals during the reporting period.